EQL Pharma's license partner Medice Arzneimittel Ptter GmbH & Co. KG. As the rstries outside of Sweden, EQL's key product Mellozzan has been launched in Denmark and Norway by EQL's licensee Medice.

The countries are the first in a series of seven where Medice contributes its market knowledge and network to quickly reach out with Mellozzan to patients. In addition to Denmark and Norway, the license also has ongoing work for registrations and subsequent launches in Medice's home market Germany, as well as the UK, Austria, Finland and Switzerland. In addition to the countries covered by Medice, licensees for Mellozzan are in various stages of registration in France, Italy, Spain, the Netherlands, Turkey and Kazakhstan.

In addition, EQL has recently entered into a global license agreement with Adalvo for Mellozzan. Mellozzan contains the sleep hormone melatonin and is indicated for children who have ADHD and suffer from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan is also indicated for the short-term treatment of jet lag in adults.